Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Prostate Cancer
Interventions: ClariCore System; Device
Lead sponsor: Precision Biopsy, Inc.; Industry
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
Interventions: Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Nonalcoholic Fatty Liver Disease, Physician
Interventions: Interview, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ulcer Foot, Diabetes
Interventions: SFDI Imaging; Device
Lead sponsor: Modulated Imaging Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Constrictive Pericarditis
Interventions: CD Leycom/Millar Instruments conductance catheter; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide, Laboratory Biomarker Analysis, Pembrolizumab; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Latent Autoimmune Diabetes in Adult
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 25 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Raloxifene followed by combination therapy, Exemestane followed by combination therapy; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Interventions: Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 17 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Insomnia, Traumatic Brain Injury
Interventions: CBT-I, ABT-I; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diabetes
Interventions: Study Arm A, Study Arm B, Study Arm C, Study Arm D; Dietary Supplement
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Osteoarthritis
Interventions: celecoxib, Oxycodone, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Marijuana Use, Marijuana Dependence, Tobacco Use, Alcohol Use, Unspecified
Interventions: Domain-Specific Episodic Future Thinking; Behavioral
Lead sponsor: Michael Sofis; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Sudbury, Massachusetts

Conditions: Acute Myeloid Leukemia, Lymphoblastic Leukemia, Acute Leukemia, Non Hodgkins Lymphoma, Chronic Myeloid Leukemia
Interventions: IM-TMI (3Gy), IM-TMI (6Gy), IM-TMI (9Gy), IM-TMI (12Gy); Radiation
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ebola Virus Disease
Interventions: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water; Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Decatur, Georgia • St Louis, Missouri

Conditions: Parkinson Disease
Interventions: Lenrispodun, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 31 more

Conditions: Obesity
Interventions: Placebo, HMB; Dietary Supplement
Lead sponsor: Metabolic Technologies Inc.; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Rosacea
Interventions: doxycycline; Drug
Lead sponsor: CollaGenex Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 7
States / cities: Omaha, Nebraska • Las Vegas, Nevada • Arlington, Texas + 4 more

Conditions: Sleep Deprivation, Circadian Dysregulation, Shift-Work Sleep Disorder
Interventions: sleep extension & circadian alignment; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: LEE011, Letrozole, BYL719; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Tampa, Florida + 5 more

Conditions: Newly Diagnosed MGMT Unmethylated Glioblastoma
Interventions: D2C7-IT, 2141-V11; Drug
Lead sponsor: Darell Bigner; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bedwetting
Interventions: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS; Device
Lead sponsor: Heidi Stephany; Other
Eligibility: 5 Years to 16 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Ixazomib Citrate, Lenalidomide, Placebo Administration, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 221
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Arroyo Grande, California + 154 more

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Honolulu, Hawaii

Search by objective public record fields.

ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease

Optical Imaging For Assessment of Foot Perfusion

New Methods to Diagnose Constrictive Pericarditis

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Genetics of Latent Autoimmune Diabetes in Adults

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury

Vitamins C and Vitamin E and Cardiovascular Risk

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

Examining Effects of Domain Specific Episodic Future Thinking on Cannabis Use

Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies

Immunology of Ebola Vaccine

Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism

Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens

Cardiometabolic Risk of Shiftwork

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Foot Neuromodulation for Nocturnal Enuresis

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer